Review



immunohistochemical data  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Human Protein Atlas immunohistochemical data
    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) <t>Immunohistochemical</t> (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.
    Immunohistochemical Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+data/pmc13264208-473-1-15?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    immunohistochemical data - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "ExIR enables prioritizing driver and biomarker genes from omics data in a reference free manner"

    Article Title: ExIR enables prioritizing driver and biomarker genes from omics data in a reference free manner

    Journal: iScience

    doi: 10.1016/j.isci.2026.116303

    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.
    Figure Legend Snippet: Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.

    Techniques Used: Immunohistochemical staining, Immunostaining



    Similar Products

    immunohistochemical data  (Human Protein Atlas)
    86
    Human Protein Atlas immunohistochemical data
    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) <t>Immunohistochemical</t> (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.
    Immunohistochemical Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+data/pmc13264208-473-1-15?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    immunohistochemical data - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    cancer a e immunohistochemical ihc data  (Human Protein Atlas)
    86
    Human Protein Atlas cancer a e immunohistochemical ihc data
    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) <t>Immunohistochemical</t> <t>(IHC)</t> data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.
    Cancer A E Immunohistochemical Ihc Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+data/pmc13264208-204-14-22?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    cancer a e immunohistochemical ihc data - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    immunohistochemistry ihc data  (Human Protein Atlas)
    86
    Human Protein Atlas immunohistochemistry ihc data
    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) <t>Immunohistochemical</t> <t>(IHC)</t> data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.
    Immunohistochemistry Ihc Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+data/pm42286393-103-1-6?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    immunohistochemistry ihc data - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    ihc data  (Human Protein Atlas)
    86
    Human Protein Atlas ihc data
    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) <t>Immunohistochemical</t> <t>(IHC)</t> data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.
    Ihc Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ihc+data/pm42234523-51-0-4?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    ihc data - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.

    Journal: iScience

    Article Title: ExIR enables prioritizing driver and biomarker genes from omics data in a reference free manner

    doi: 10.1016/j.isci.2026.116303

    Figure Lengend Snippet: Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.

    Article Snippet: Additionally, immunohistochemical data for the specific lung adenocarcinoma (LUAD) subtype analyzed were available from the Human Protein Atlas.

    Techniques: Immunohistochemical staining, Immunostaining

    Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.

    Journal: iScience

    Article Title: ExIR enables prioritizing driver and biomarker genes from omics data in a reference free manner

    doi: 10.1016/j.isci.2026.116303

    Figure Lengend Snippet: Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268).(J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470). Per the Human Protein Atlas database usage guidelines, the link to the immunostaining images of all of the selected proteins in normal pneumocytes and LUAD samples are included as hyperlinks within the figure legend. Ab: antibody; LUAD: lung adenocarcinoma.

    Article Snippet: Figure 4 Differential immunoreactivity of known and novel ExIR-predicted LUAD biomarkers between normal and cancer samples (A–E) Immunohistochemical (IHC) data from the Human Protein Atlas database in LUAD and normal lung tissue for top five known LUAD biomarkers. (A) SFTPC–ExIR rank #1, LUAD (negative intensity; patient ID: 1847) and normal pneumocytes (quantity: 75%–25%; strong intensity; patient ID: 2268). (B) SPP1—ExIR rank #117, LUAD (quantity: >75%; moderate intensity; patient ID: 537) and normal pneumocytes (not detected; patient ID: 2268). (C) CBLC—ExIR rank #140, LUAD (quantity: >75%; moderate intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2417). (D) MDK—ExIR rank #247, LUAD (quantity: 75%–25%; strong intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2222). (E) MRC1 – ExIR rank #471, LUAD (undetected; patient ID: 1932) and normal macrophages (quantity: 75%–25%; strong intensity; patient ID: 2208). (F–I) IHC data of top five ExIR-predicted LUAD biomarkers (excluding SFTPC rank #1 already in a). (F) AGER – ExIR rank #2, LUAD (not detected; patient ID: 3144) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 4840). (G) EMP2 – ExIR rank #3, LUAD (not detected; patient ID: 1847) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2101). (H) CAV1 – ExIR rank #4, LUAD (not detected; patient ID: 1249) and normal pneumocytes (quantity: >75%; strong intensity; patient ID: 2208). i, RTKN2 – ExIR rank 5, LUAD (not detected; patient ID: 3003) and normal pneumocytes (quantity: <25%; moderate intensity; patient ID: 2268). (J–N) IHC data of top six ExIR-predicted LUAD up-regulated biomarkers (excluding FAM83A rank #2, for which no IHC data was available). (J) PYCR1 – ExIR rank #1, LUAD (quantity: >75%; moderate intensity; patient ID: 2777) and normal pneumocytes (not detected; patient ID: 2208). (K) TOP2A – ExIR rank #3, LUAD (quantity: 75%–25%; strong intensity; patient ID: 3003) and normal pneumocytes (quantity: 75%–25%; weak intensity; patient ID: 2101). (L) MMP11 – ExIR rank #4, LUAD (quantity: >75%; weak intensity; patient ID: 1847) and normal pneumocytes (not detected; patient ID: 2438). (M) TEDC2– ExIR rank 5, LUAD (quantity: 75%–25%; moderate intensity; patient ID: 4208) and normal pneumocytes (not detected; patient ID: 1470). (N) IQGAP3– ExIR rank 6, LUAD (quantity: >75%; strong intensity; patient ID: 3048) and normal pneumocytes (not detected; patient ID: 1470).

    Techniques: Immunohistochemical staining, Immunostaining